Jonathan P. Foster, Chief Financial Officer of Moleculin Biotech, Inc. (NASDAQ:MBRX), filed a Form 4 on November 18, 2026, disclosing the vesting of restricted stock units and a related tax withholding transaction dated November 16, 2026.

Key Highlights

  • RSU conversion: 362 restricted stock units were converted into 362 shares of common stock on November 16, 2026, via transaction code M.
  • Tax withholding: 89 shares were disposed of at $7.14 per share on November 16, 2026, to cover taxes upon vesting, via transaction code F.
  • Resulting common stock ownership: Foster directly beneficially owns 20,506 shares of common stock following the reported transactions.
  • Remaining RSUs: Foster holds 70,492 restricted stock units following the reported transaction.
  • Vesting schedule: The RSU award vests 50% on grant and 50% in 18 equal installments over 18 months, according to the filing.
  • Conversion basis: Each restricted stock unit represents a contingent right to receive one share of company common stock on a one-for-one basis.

Foster RSU Vesting and Tax Withholding Details at Moleculin Biotech

According to the Form 4 filed with the SEC on November 18, 2026, Jonathan P. Foster, serving as Chief Financial Officer of Moleculin Biotech, Inc. (NASDAQ:MBRX), reported two transactions in common stock and one derivative security transaction, all dated November 16, 2026. The filing identifies Foster solely as an officer and does not indicate director or 10% owner status.

The filing discloses that 362 restricted stock units were converted into 362 shares of common stock via an M-coded transaction, bringing Foster's directly held common stock position to 20,595 shares before the subsequent withholding. Immediately following, 89 shares were withheld at a price of $7.14 per share under transaction code F, described in the filing as "shares withheld for payment of taxes upon vesting of restricted stock unit awards," reducing his directly held common stock to 20,506 shares.

In Table II, the filing reports that Foster's derivative security position in restricted stock units decreased by 362 units through the M-coded conversion, leaving him with 70,492 restricted stock units held directly. The filing states the vesting schedule as: "(i) 50% on grant; and (ii) 50% in 18 equal installments over 18 months." The conversion price of the derivative security is listed as $0, and each restricted stock unit represents a contingent right to receive one share of company common stock. The filing was signed by Jonathan P. Foster and dated November 18, 2026.

What Was Disclosed

Moleculin Biotech CFO Jonathan P. Foster reported the vesting of 362 restricted stock units into common stock and the withholding of 89 shares at $7.14 for tax purposes on November 16, 2026, leaving him with 20,506 shares and 70,492 RSUs directly held.